EUVIMEDEUVIMED entdecken
Open Access

Ophthalmate is a new regulator of motor functions via CaSR: implications for movement disorders

Sammy Alhassen, Derk Hogenkamp, Hung Anh Nguyen, Saeed Al Masri, Geoffrey W Abbott, Olivier Civelli, Amal Alachkar iD

Brain · 2024

DOI: 10.1093/brain/awae097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Sammy Alhassen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California Irvine, Irvine, CA 92697, USA. Hauptthemen laut MEDLINE: Receptors, Calcium-Sensing, Levodopa, Motor Activity. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, US National Institutes of Health, Eric L. and Lila D. Nelson Chair in Neuropharmacology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dopamine’s role as the principal neurotransmitter in motor functions has long been accepted. We broaden this conventional perspective by demonstrating the involvement of non-dopaminergic mechanisms. In mouse models of Parkinson’s disease, we observed that L-DOPA elicited a substantial motor response even when its conversion to dopamine was blocked by inhibiting the enzyme aromatic amino acid decarboxylase (AADC). Remarkably, the motor activity response to L-DOPA in the presence of an AADC inhibitor (NSD1015) showed a delayed onset, yet greater intensity and longer duration, peaking at 7 h, compared to when L-DOPA was administered alone. This suggests an alternative pathway or mechanism, independent of dopamine signalling, mediating the motor functions. We sought to determine the metabolites associated with the pronounced hyperactivity observed, using comprehensive metabolomics analysis. Our results revealed that the peak in motor activity induced by NSD1015/L-DOPA in Parkinson’s disease mice is associated with a surge (20-fold) in brain levels of the tripeptide ophthalmic acid (also known as ophthalmate in its anionic form). Interestingly, we found that administering ophthalmate directly to the brain rescued motor deficits in Parkinson’s disease mice in a dose-dependent manner. We investigated the molecular mechanisms underlying ophthalmate’s action and discovered, through radioligand binding and cAMP-luminescence assays, that ophthalmate binds to and activates the calcium-sensing receptor (CaSR). Additionally, our findings demonstrated that a CaSR antagonist inhibits the motor-enhancing effects of ophthalmate, further solidifying the evidence that ophthalmate modulates motor functions through the activation of the CaSR. The discovery of ophthalmate as a novel regulator of motor function presents significant potential to transform our understanding of brain mechanisms of movement control and the therapeutic management of related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Calcium-SensingLevodopaMotor ActivityAnimalsMiceMice, Inbred C57BLMovement DisordersMaleOligopeptidesDopamineHumansDisease Models, Animal

Stichwörter der Autor:innen

CaSRParkinson’s diseasedopaminemotorophthalmate

Substanzen

Receptors, Calcium-SensingLevodopaOligopeptidesDopamine

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California Irvine, Irvine, CA 92697, USA.
  • Bioelectricity Laboratory, Department of Physiology and Biophysics, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.
  • Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA 92697, USA.
  • Institute for Genomics and Bioinformatics, School of Information and Computer Sciences, University of California Irvine, Irvine, CA 92697, USA.
  • UC Irvine Center for the Neurobiology of Learning and Memory, University of California Irvine, Irvine, CA 92697, USA.

ORCID-Profile: Amal Alachkar

Förderung

  • NINDS NIH HHS
  • US National Institutes of Health
  • Eric L. and Lila D. Nelson Chair in Neuropharmacology
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Alhassen, S., Hogenkamp, D., Nguyen, H. A., Al Masri, S., Abbott, G. W., Civelli, O., & Alachkar, A. (2024). Ophthalmate is a new regulator of motor functions via CaSR: implications for movement disorders. Brain. https://doi.org/10.1093/brain/awae097

Vancouver

Alhassen S, Hogenkamp D, Nguyen HA, Al Masri S, Abbott GW, Civelli O, et al. Ophthalmate is a new regulator of motor functions via CaSR: implications for movement disorders. Brain. 2024. doi:10.1093/brain/awae097

BibTeX
@article{Alhassen2024,
  author = {Alhassen, Sammy and Hogenkamp, Derk and Nguyen, Hung Anh and Al Masri, Saeed and Abbott, Geoffrey W and Civelli, Olivier and Alachkar, Amal},
  title = {Ophthalmate is a new regulator of motor functions via CaSR: implications for movement disorders},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awae097}
}
Kostenlos starten →